Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc., trading under the ticker symbol VOR, is at the forefront of cell and genome engineering, specifically focusing on hematopoietic stem cells (HSCs). Headquartered in Cambridge, Massachusetts, Vor Bio aims to revolutionize the treatment of hematological cancers, particularly acute myeloid leukemia (AML). The company’s pioneering platform involves engineering hematopoietic stem cells (eHSCs) to generate healthy and functional cells with beneficial modifications. These modifications protect the blood and bone marrow from the adverse effects of antigen-targeted therapies while leaving cancer cells vulnerable.
Key Products and Innovations:
- VOR33 (Trem-cel) - Vor Bio’s lead program, a CRISPR/Cas9 genome-edited allogeneic HSC transplant that lacks the CD33 protein. This product is designed to replace standard transplants for AML patients and potentially other blood cancers.
- VCAR33ALLO - A CD33-directed CAR-T cell therapy derived from healthy transplant donor cells. This approach aims to provide more potent and durable responses in the post-transplant setting without on-target toxicity.
Recent Achievements and Collaborations:
- Secured a non-exclusive worldwide license from Editas Medicine for ex-vivo Cas9 gene-edited HSC therapies.
- Partnership with Janssen for the preclinical development of CD33-deleted allografts and their synergistic effects with Janssen's CD33-targeted immunotherapy candidate.
Clinical Trials and Research:
- VBP101 Clinical Trial - Ongoing Phase 1/2a study of trem-cel in AML patients, showing promising engraftment results and hematologic protection.
- VCAR33ALLO Clinical Trial (VBP301) - A Phase 1/2 study involving CAR-T cell therapy derived from healthy transplant donors, showing initial successful dosing and manufacturing capabilities.
Financial Updates: In its latest quarterly report, Vor Bio announced positive financial outcomes, including an extended cash runway into the second half of 2025. The company is focused on executing its clinical trials and expanding its platform to include additional innovative therapies.
Future Outlook: Vor Bio is set to present at major scientific conferences, including the American Society of Hematology (ASH) Annual Meeting, where it will share significant preclinical and clinical data. The company is also looking forward to additional data releases from its clinical trials by year-end, which could further validate their treatment system for AML.
For more updates, visit www.vorbio.com.
Vor Bio (Nasdaq: VOR) reported encouraging updates in its latest financial results for Q1 2022, emphasizing its focus on the VBP101 clinical trial for VOR33, targeting AML. Initial clinical data for VOR33 is expected in 2H 2022. Significant advancements were presented at the Keystone Symposia, showcasing the efficacy of multiplex editing platforms. The company’s in-house manufacturing facility in Cambridge is set to enhance production efficiency. However, net loss rose to $22.7 million, up from $13.7 million in Q1 2021, reflecting increased R&D and administrative expenses.
Vor Biopharma (Nasdaq: VOR) announced participation in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference is set for May 13, 2022, featuring virtual 1x1 meetings. They will also present at the H.C. Wainwright Global Investment Conference on May 24, 2022, with a pre-recorded on-demand presentation available starting at 7:00 AM ET. Investors can access the webcast replay on the company's website, www.vorbio.com. Vor Bio focuses on engineering hematopoietic stem cells for targeted therapies in blood cancers.
Vor Bio (Nasdaq: VOR) announced acceptance of two abstracts for presentation at the Keystone Symposia on Precision Genome Engineering (April 27 - May 1, 2022). The presentations will detail Vor Bio’s innovative multiplex editing capability in targeting cancer cells while preserving healthy ones, specifically for patients with acute myeloid leukemia (AML). Dr. Tirtha Chakraborty emphasized the potential of this method to minimize risks associated with traditional therapies. Vor Bio is advancing its lead program, VOR33, aimed at improving outcomes for AML patients.
Vor Bio (Nasdaq: VOR) announced the retirement of Chief Medical Officer Dr. Christopher Slapak as part of a transition to enhance its clinical capabilities. As the clinical team recruits patients for the ongoing Phase 1/2a VBP101 study of VOR33 in high-risk AML patients, an executive search for Dr. Slapak’s replacement is underway. CEO Dr. Robert Ang emphasized the successful build-up of the clinical team and infrastructure necessary for this next phase, with initial data anticipated in the second half of 2022.
Vor Bio (NASDAQ: VOR) has entered into a significant agreement with Akron BioProducts to develop and manufacture cGMP nucleases. This partnership aims to enhance Vor Bio's capabilities in engineering gene-modified cell therapies for blood cancers. The collaboration supports both companies' strategic investments in advanced manufacturing facilities, expected to improve production efficiency. Vor Bio's new clinical manufacturing site in Cambridge, MA, anticipated to be operational in 2022, will facilitate the development of its eHSC and CAR-T product pipeline.
Vor Bio (Nasdaq: VOR) reported its financial results for 2021 and provided business updates. The company anticipates initial clinical data for its engineered hematopoietic stem cell candidate, VOR33, in the second half of 2022. The FDA granted VOR33 Orphan-drug designation and Fast Track status for acute myeloid leukemia (AML), allowing potential expedited development. Cash reserves of $207.5 million are expected to fund operations into Q4 2023. R&D expenses rose to $47.5 million in 2021, while the net loss increased to $68.9 million, reflecting ongoing investments in clinical trials.
Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced participation in three upcoming investor conferences. The Cowen’s 42nd Annual Healthcare Conference will take place on March 7, 2022, at 2:10 PM ET. Following that, the Oppenheimer's 32nd Annual Healthcare Conference is scheduled for March 15, 2022, at 1:20 PM ET. Finally, a Fireside Chat at the Barclays Global Healthcare Conference will occur on March 17, 2022, at 8:00 AM ET. Live webcasts and archived replays will be available on their website.
Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced that Dr. Robert Ang, the President and CEO, will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 2:20 PM ET. A live webcast will be available on the Company's website, with an archived replay following the conference. Vor Biopharma focuses on changing the standard of care for blood cancer patients by engineering hematopoietic stem cells for targeted therapies post-transplant.
Vor Biopharma (Nasdaq: VOR) announced participation in two virtual investor conferences. The first is the H.C. Wainwright BioConnect 2022, with a pre-recorded presentation available on January 10, 2022, starting at 7:00 AM ET. The second event is the 2022 B Riley Virtual Oncology Conference, featuring a live webcast fireside chat on January 27, 2022, at 10:30 AM ET. Both presentations will be accessible through the company’s website, along with archived replays.
Vor Biopharma focuses on engineering hematopoietic stem cells to improve blood cancer treatments.
Vor Biopharma (Nasdaq: VOR) announced that Dr. Robert Ang, the company's President and CEO, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2021, at 12:40 PM ET. Investors can access a live webcast of the chat on the company’s website, with an archived replay available afterward. Vor Biopharma focuses on transforming care for blood cancer patients by engineering hematopoietic stem cells for targeted therapies following transplantation.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
What is Vor Biopharma Inc. known for?
What are the main products of Vor Biopharma Inc.?
Where is Vor Biopharma Inc. located?
What recent achievements has Vor Biopharma Inc. made?
What clinical trials are currently being conducted by Vor Biopharma Inc.?
What is the potential impact of Vor Biopharma Inc.'s platform?
How can I stay updated on Vor Biopharma Inc.'s progress?
What financial updates were provided by Vor Biopharma Inc. recently?
What upcoming milestones is Vor Biopharma Inc. expecting?
What collaborations has Vor Biopharma Inc. entered into?
